Summary & Overview
HCPCS C9303: Zolbetuximab-clzb Injection, 1 mg
HCPCS Level II code C9303 designates the injectable biologic zolbetuximab-clzb measured per 1 mg. As a specific drug J/G/C-series code alternative within HCPCS Level II, C9303 is used on medical claims to capture the administered quantity of this monoclonal antibody therapy. Nationwide, accurate use of this code affects clinical documentation, reimbursement for high-cost oncology infusions, and tracking of utilization for specialty pharmaceuticals.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for zolbetuximab-clzb as an injectable therapy, standard settings where the drug is administered (infusion centers, hospital outpatient departments, and physician offices), and the common modifiers associated with infusion and professional services.
The publication provides benchmarks and operational considerations relevant to billing and claims processing, highlights payer coverage patterns and prior authorization practices where available, and outlines coding nuances for per-milligram billing. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code C9303 represents injection, zolbetuximab-clzb, 1 mg. This code describes the drug product and dosage unit used for intravenous or other parenteral administration of zolbetuximab-clzb on a per-milligram basis.
-
Service type: Drug administration (injectable biologic)
-
Typical site of service: Infusion center, hospital outpatient department, or physician office infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with metastatic, claudin 18.2–positive gastric adenocarcinoma receives intravenous targeted monoclonal antibody therapy with C9303 (zolbetuximab-clzb) as part of systemic oncology care. The patient presents to an outpatient oncology infusion center for cycle-based administration. Pre-infusion workflow includes verification of indication and prior authorization, review of recent labs (complete blood count, liver function tests), consent, and assessment for infusion reaction risk. On the day of service the oncology nurse performs baseline vital signs, establishes peripheral IV access or confirms implanted port patency, and prepares weight-based or protocol-specified dose using C9303 units (expressed per mg). The infusion is delivered over the time interval specified by the prescribing oncologist; nursing monitors for hypersensitivity, infusion-related reactions, and other adverse events. Billing captures the administered drug as C9303 per mg, plus any applicable infusion administration CPT codes, and documents relevant diagnosis codes supporting medical necessity. Common modifiers may be appended for circumstances such as unusual services, bilateral separate procedures, or suspended procedures due to patient intolerance.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |